Københavns Universitet, Det Sundhedsvidenskabelige Fakultet

CORS Annual Conference 2019: Public health and innovation – Is regulation a friend or a foe?


Date and time

Monday 18. November, 2019 at 09:00

Location

Henrik Dam auditoriet, Det Sundhedsvidenskabelige Fakultet, KU
Mærsk Tårnet, Blegdamsvej 3
2200 København N

Organizer

Copenhagen Centre for Regulatory Science, Department of Pharmacy, University of Copenhagen
+45 35333311
cors@sund.ku.dk

CORS Conference 2019

We are pleased to announce the Copenhagen Centre for Regulatory Science 5th annual conference.

The regulatory system for market authorisation is a critical factor in the development of new medicines. This system has to take into consideration the protection of public health while, at the same time, ensuring that patients have timely access to medicines, including the ones that address unmet medical needs. During the past decades, a drop in the introduction of new innovative drugs has been observed, despite progress in biomedical research and development. Although the reasons for this innovation deficit are not fully understood, many observers see the increasing demands of the regulatory systems as one of the main drivers. 
This year, the Annual CORS conference will focus on the role of regulation in both protecting public health and promoting innovation. Through discussions and presentations by invited speakers, we will explore and discuss what the implications of incentives and requirements set up by medicine regulations represent for innovation, public health and ethics.

The conference is open for attendance by all interested parties. 

Confirmed speakers:

Jonathan Kimmelman
Jonathan Kimmelman
Jonathan Kimmelman, PhD, is James McGill Professor of Biomedical Ethics at McGill University, and directs the Biomedical Ethics Unit as well as his own research group, STREAM (Studies in Translation, Ethics and Medicine). Kimmelman’s research centers on ethical, policy, and scientific dimensions of clinical development. In addition to his book, Gene Transfer and the Ethics of First-in-Human Experiments (Cambridge Press, 2010), major publications have appeared in Science, JAMA, BMJ, and Hastings Center Report.  Kimmelman received the Maud Menten New Investigator Prize (2006), a CIHR New Investigator Award (2008), a Humboldt Bessel Award (2014), and was elected a Hastings Center Fellow (2018).  He has sat on various advisory bodies within the U.S. NHLBI and NIAID, served for four tours of duty on U.S. National Academies of Medicine committees, and chaired the International Society of Stem Cell Research Guidelines for Stem Cell Research and Clinical Translation revision task force 2015-16. His research has been covered in major media outlets, including NPR’s All Things Considered, STATNews, and Nature. Kimmelman is deputy editor at Clinical Trials, and serves as an associate editor at PLoS Biology.

Hans Georg EichlerHans-Georg Eichler

Hans-Georg Eichler, M.D., M.Sc., is the Senior Medical Officer of the European Medicines Agency, where he is responsible for coordinating activities between the Agency’s scientific committees and giving advice on scientific and public health issues. From 2015 to 2018 he was the scientific lead for the IMI ADAPT SMART consortium on Adaptive Licensing. Prior to joining the European Medicines Agency, Dr. Eichler was at the Medical University of Vienna in Austria for 15 years. He was vice-rector for Research and International Relations since 2003, and professor and chair of the Department of Clinical Pharmacology since 1992. His other previous positions include president of the Vienna School of Clinical Research and co-chair of the Committee on Reimbursement of Drugs of the Austrian Social Security Association. His industry experience includes time spent at Ciba-Geigy Research Labs, U.K., and Outcomes Research at Merck & Co., in New Jersey. Dr. Eichler graduated with an M.D. from Vienna University Medical School and a Master of Science degree in Toxicology from the University of Surrey in Guildford, U.K. He trained in internal medicine and clinical pharmacology at the Vienna University Hospital as well as at Stanford University.

The full programme will be disclosed soon.
The conference will take place in Henrik Dam auditoriet in the Mærsk Tower. Lunch, snacks and refreshments will be provided. 
For more information about CORS, visit our website: www.cors.ku.dk

Event Location

Organizer Contact Information

Copenhagen Centre for Regulatory Science, Department of Pharmacy, University of Copenhagen
+45 35333311
cors@sund.ku.dk